572 related articles for article (PubMed ID: 28441077)
1. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
Li F; Sun M; Guo J; Ma A; Zhao B
Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
[TBL] [Abstract][Full Text] [Related]
2. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
3. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
Song S; Yu X; Zhang P; Gu X; Dai H
BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
Son BK; Kwak HW; Kim ES; Yu SY
Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106
[TBL] [Abstract][Full Text] [Related]
5. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
6. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
[TBL] [Abstract][Full Text] [Related]
7. Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.
Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
BMC Ophthalmol; 2017 Jun; 17(1):90. PubMed ID: 28610573
[TBL] [Abstract][Full Text] [Related]
8. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
10. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
[TBL] [Abstract][Full Text] [Related]
11. OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.
Tang F; Qin X; Lu J; Song P; Li M; Ma X
Retina; 2020 Apr; 40(4):773-785. PubMed ID: 30640282
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal conbercept for branch retinal vein occlusion induced macular edema: one initial injection versus three monthly injections.
Chen X; Hu TM; Zuo J; Wu H; Liu ZH; Zhan YX; Xia Y; Wang J; Wei W
BMC Ophthalmol; 2020 Jun; 20(1):225. PubMed ID: 32527234
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.
Liu W; Li Y; Cao R; Bai Z; Liu W
Medicine (Baltimore); 2020 May; 99(21):e20222. PubMed ID: 32481293
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
[TBL] [Abstract][Full Text] [Related]
15. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: 6-MONTH RESULT.
Terashima H; Hasebe H; Okamoto F; Matsuoka N; Sato Y; Fukuchi T
Retina; 2019 Jul; 39(7):1377-1384. PubMed ID: 29689025
[TBL] [Abstract][Full Text] [Related]
16. Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial.
Meng L; Yang M; Jiang X; Li Y; Han X
Int Ophthalmol; 2024 Jun; 44(1):262. PubMed ID: 38913192
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study.
Wei W; Weisberger A; Zhu L; Cheng Y; Liu C;
Ophthalmol Retina; 2020 Jan; 4(1):57-66. PubMed ID: 31902472
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Microvascular Structure Changes after Conbercept Treatment on Macular Edema Secondary to Retinal Vein Occlusion.
Song W; Jiao W; Li F; Ma A; Zhao B
Biomed Res Int; 2020; 2020():9046781. PubMed ID: 32685542
[TBL] [Abstract][Full Text] [Related]
19. The Role of Serum Inflammation-Based Factors in Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion and Its Subtypes.
Rao J; Wu N; Qu X; Hu Y; Wu Y; Cheng Y; Yan L; Huang H; Li S; Shi L; Wu X
Ophthalmic Res; 2021; 64(2):237-245. PubMed ID: 32506058
[TBL] [Abstract][Full Text] [Related]
20. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion.
Yuksel B; Karti O; Celik O; Kerci SG; Kusbeci T
Clin Exp Optom; 2018 Jan; 101(1):116-122. PubMed ID: 28922697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
